Onapgo is a wearable infusion system approved by the FDA to treat motor fluctuations in adults with advanced Parkinson’s disease. The device provides a continuous dose starting at 1 milligram (mg) per ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Some eight months into the launch of Onapgo, the Parkinson’s disease infusion pump Supernus Pharmaceuticals spent years fighting to get across the FDA finish line, the drugmaker is discovering that ...

Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl]) for ...

(RTTNews) - Supernus Pharmaceuticals, Inc. (SUPN), a biopharmaceutical company, announced on Tuesday the FDA approval of ONAPGO or apomorphine hydrochloride for the treatment of motor fluctuations in ...

Please provide your email address to receive an email when new articles are posted on . Onapgo is the first subcutaneous apomorphine infusion device approved to treat motor fluctuations in Parkinson’s ...

"Supernus's first quarter results reflect a strong start to the year, including a 56% year-over-year increase in combined revenues of our growth products and an 11% year-over-year increase in adjusted ...

Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. On its fourth attempt to pass muster with the FDA, the company’s SPN-830, now branded as ...

For full year 2026, Dec projected "total revenues to range from $840 million to $870 million, comprised of net product sales, ZURZUVAE collaboration revenues and royalty and licensing revenues." ...

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson's disease ONAPGO is a wearable subcutaneous infusion ...

"For full year 2026, the company reiterates its financial guidance" with "total revenues to range from $840 million to $870 million." (CFO Dec) "For the full year 2026, we expect combined R&D and SG&A ...